Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease

Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of gastroenterology 2023-10, Vol.42 (5), p.718-723
Main Authors: Garg, Rajat, Aggarwal, Manik, Mohammed, Abdul, Achkar, Jean Paul, Lashner, Bret, Philpott, Jessica, Cohen, Benjamin, Qazi, Taha, Rieder, Florian, Regueiro, Miguel, Click, Benjamin
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal, Humanized - adverse effects
Crohn Disease - drug therapy
Gastroenterology
Hepatology
Humans
Medicine
Medicine & Public Health
Remission Induction
Retrospective Studies
Short Report
Treatment Outcome
Ustekinumab - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.
ISSN:0254-8860
0975-0711
0975-0711
DOI:10.1007/s12664-023-01391-3